Mark Sulkowski
Impact in
- Hepatology top 0.01%
- Hepatitis C virus research
- Liver Disease and Transplantation
- Epidemiology top 0.01%
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
Papers in
- Hepatology 380
- Hepatitis C virus research 377
- Liver Disease and Transplantation 17
- Epidemiology 195
- Liver Disease Diagnosis and Treatment 125
- Hepatitis B Virus Studies 123
- Co-authors
- David L. Thomas (60 shared papers)John G. McHutchison (43 shared papers)Andrew Joseph Muir (18 shared papers)Richard K. Sterling (31 shared papers)Ira M. Jacobson (35 shared papers)Shruti H. Mehta (51 shared papers)Mark Richard Nelson (3 shared papers)Francesca J. Torriani (5 shared papers)
- Journals
- Journal of Hepatology (78 papers)Hepatology (48 papers)Gastroenterology (35 papers)Clinical Infectious Diseases (31 papers)Journal of Viral Hepatitis (24 papers)
- Partner nations
- United StatesGermanyFrance
In The Last Decade
Mark Sulkowski
471 papers receiving 38.2k citations
Mark Sulkowski's Hit Papers
Peers
Comparison fields: 5 of 160
- Hepatology 30.0k
- Epidemiology 20.0k
- Infectious Diseases 5.7k
- Virology 1.1k
- Transplantation 545
Countries citing papers authored by Mark Sulkowski
This map shows the geographic impact of Mark Sulkowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Sulkowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Sulkowski more than expected).
Fields of papers citing papers by Mark Sulkowski
This network shows the impact of papers produced by Mark Sulkowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Sulkowski. The network helps show where Mark Sulkowski may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Sulkowski, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 488 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡ Hit paper breakdown → | 2006 | 3959 |
| 2 | Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Hit paper breakdown → | 2009 | 2908 |
| 3 | Boceprevir for Untreated Chronic HCV Genotype 1 Infection Hit paper breakdown → | 2011 | 2068 |
| 4 | Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection Hit paper breakdown → | 2014 | 1123 |
| 5 | Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection Hit paper breakdown → | 2009 | 1002 |
| 6 | Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection Hit paper breakdown → | 2014 | 971 |
| 7 | Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options Hit paper breakdown → | 2013 | 908 |
| 8 | Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection Hit paper breakdown → | 2009 | 893 |
| 9 | Hepatotoxicity Associated With Antiretroviral Therapy in Adults Infected With Human Immunodeficiency Virus and the Role of Hepatitis C or B Virus Infection Hit paper breakdown → | 2000 | 822 |
| 10 | Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection Hit paper breakdown → | 2015 | 697 |
| 11 | Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease Hit paper breakdown → | 2015 | 681 |
| 12 | Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study Hit paper breakdown → | 2014 | 664 |
| 13 | Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus Hit paper breakdown → | 2010 | 611 |
| 14 | Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection Hit paper breakdown → | 2011 | 605 |
| 15 | Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection Hit paper breakdown → | 2017 | 569 |
| 16 | Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin Hit paper breakdown → | 2014 | 447 |
| 17 | 2002 | 447 | |
| 18 | Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1 Hit paper breakdown → | 2015 | 386 |
| 19 | 2010 | 383 | |
| 20 | 2002 | 379 |
About Mark Sulkowski
Mark Sulkowski is a scholar working on Hepatology, Epidemiology, Infectious Diseases, Rheumatology and Emergency Medicine, having authored 488 papers that have together received 39.8k indexed citations. Recurring topics across this work include Hepatitis C virus research (377 papers), Liver Disease Diagnosis and Treatment (125 papers), Hepatitis B Virus Studies (123 papers), HIV/AIDS drug development and treatment (61 papers), Systemic Lupus Erythematosus Research (35 papers), Chronic Lymphocytic Leukemia Research (19 papers), HIV-related health complications and treatments (19 papers) and Liver Disease and Transplantation (17 papers). The work is most often cited by research in Hepatology (30.0k citations), Epidemiology (20.0k citations), Infectious Diseases (5.7k citations), Virology (1.1k citations) and Transplantation (545 citations). Mark Sulkowski has collaborated with scholars based in United States, Germany and France. Frequent co-authors include David L. Thomas, John G. McHutchison, Andrew Joseph Muir, Richard K. Sterling, Ira M. Jacobson, Shruti H. Mehta, Mark Richard Nelson, Francesca J. Torriani, Ricard Solà and Nathan Clumeck. Their work appears in journals such as Journal of Hepatology, Hepatology, Gastroenterology, Clinical Infectious Diseases and Journal of Viral Hepatitis.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.